Furthermore, since the loss of monoamine neurotransmitters (e.g., Dopamine) is of pivotal importance in PD and AD patient brains, attributed to monoamine oxidases (MAOs: MAO-A and MAO-B), therapeutic agents also involve MAO inhibitors. The gene discussed is MAOA; the disease is Parkinson disease.